SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-062011
Filing Date
2023-11-09
Accepted
2023-11-09 16:05:36
Documents
73
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-20230930.htm   iXBRL 10-Q 3100088
2 EX-10.1 ntla-ex10_1.htm EX-10.1 36358
3 EX-10.2 ntla-ex10_2.htm EX-10.2 243852
4 EX-31.1 ntla-ex31_1.htm EX-31.1 14937
5 EX-31.2 ntla-ex31_2.htm EX-31.2 14954
6 EX-32.1 ntla-ex32_1.htm EX-32.1 9100
7 GRAPHIC img231249033_0.jpg GRAPHIC 3456
  Complete submission text file 0000950170-23-062011.txt   12425115

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ntla-20230930_def.xml EX-101.DEF 235345
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ntla-20230930.xsd EX-101.SCH 57692
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ntla-20230930_cal.xml EX-101.CAL 44329
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ntla-20230930_pre.xml EX-101.PRE 363951
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ntla-20230930_lab.xml EX-101.LAB 484090
67 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20230930_htm.xml XML 2868201
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 231392285
SIC: 2835 In Vitro & In Vivo Diagnostic Substances